Frenalytics provides an individualized treatment program to improve a patient’s quality of life, rather than a generic one, because no two patients should be treated alike.
Our Research & Development efforts span over a decade, since the inception of the first version of Frenalytics in 2008. Here’s what we’ve published since then:
The founders of Think Group Holdings were awarded a United States Patent in 2016 for a unique approach to rehabilitation driven by computer algorithms to determine a patient’s condition and personalized datasets to help improve outcomes.
Here’s what we found:
• Existing options for rehabilitation did not leverage 21st-century technologies available to brain-injured patients and their care teams;
• Our proposed approach to rehabilitation, which digitizes established neurological tests to evaluate a patient’s condition, renders a determination based on the a patient’s condition, and generates a therapy protocol utilizing personalized datasets from a patient’s care team, is unique and merititious;
• Our web-based solution allows patients to access affordable therapy regardless of where they receive care, who assists in their treatment, or what physical condition they are in.